BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Amniocentesis
,
Vitamin E
,
rs2230926
,
VEGFA
,
Fatty acid metabolic process
,
Ischemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Plk1
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Testes
Skeletal muscle psoas
Thymus gland
Fetal liver
Granulocyte-macrophage progenitor cell of bone marrow
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (2 of 2)
L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (1 of 2)
L1000 CMAP - Hepatocellular carcinoma Hep G2 cells with shRNA-mediated gene knockdown (1 of 2)
L1000 CMAP Prostate cancer VCaP cells with gene overexpression perturbations
L1000 CMAP Breast cancer MCF7 cells with gene overexpression perturbations
Explore Curated Studies Results
Literature
Most Relevant Literature
Hornerin mediates phosphorylation of the polo-box domain in Plk1 by Chk1 to induce death in mitosis.
Genetic enhancers of partial PLK1 inhibition reveal hypersensitivity to kinetochore perturbations.
Plk1 promotes renal tubulointerstitial fibrosis by targeting autophagy/lysosome axis.
Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer…
Mechanisms of nuclear pore complex disassembly by the mitotic Polo-like kinase 1 (PLK-1) in C. elega…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Sma…
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-…
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ